PURPOSE: To study the association between baseline heart rate and outcome in patients with multiple organ dysfunction (MODS) as well as the course of heart rate over the first 4 days during MODS. METHODS: Prospective observational study in 89 patients with MODS, defined as an APACHE-II score ≥20. Baseline heart rate (HR(0)) was determined over a 60-minute period at the time of MODS diagnosis. 28-day all-cause mortality was the primary endpoint of the study, a fall of the APACHE-II score by 4 points or more from day 0 to day 4 constituted the secondary endpoint. Hazard ratios for heart rate of 90 beats per minute (bpm) or greater relative to less than 90 bpm were calculated using Cox proportional hazards model and adjusted for confounding variables. RESULTS: Median baseline heart rate was 83 bpm in survivors and 92 bpm in non-survivors (p = 0.048). 28-day mortality was 32 and 61% in patients with HR(0) < 90 bpm and HR(0) ≥ 90 bpm, respectively. The adjusted hazard ratio for 28-day mortality was 2.30 (95% confidence interval 1.21-4.36, p = 0.001) for HR(0) ≥ 90 bpm relative to HR(0) < 90 bpm. No correlation was found between baseline heart rate and the secondary endpoint. From day 0 to day 4, heart rate remained elevated in all patients, as well as in survivors and non-survivors. CONCLUSIONS: A heart rate ≥90 bpm at the time of MODS diagnosis is an independent risk factor for increased 28-day mortality. As in patients with cardiovascular conditions such as coronary heart disease or chronic heart failure, heart rate might constitute a target for heart rate-lowering therapy in the narrow initial treatment window of MODS.
PURPOSE: To study the association between baseline heart rate and outcome in patients with multiple organ dysfunction (MODS) as well as the course of heart rate over the first 4 days during MODS. METHODS: Prospective observational study in 89 patients with MODS, defined as an APACHE-II score ≥20. Baseline heart rate (HR(0)) was determined over a 60-minute period at the time of MODS diagnosis. 28-day all-cause mortality was the primary endpoint of the study, a fall of the APACHE-II score by 4 points or more from day 0 to day 4 constituted the secondary endpoint. Hazard ratios for heart rate of 90 beats per minute (bpm) or greater relative to less than 90 bpm were calculated using Cox proportional hazards model and adjusted for confounding variables. RESULTS: Median baseline heart rate was 83 bpm in survivors and 92 bpm in non-survivors (p = 0.048). 28-day mortality was 32 and 61% in patients with HR(0) < 90 bpm and HR(0) ≥ 90 bpm, respectively. The adjusted hazard ratio for 28-day mortality was 2.30 (95% confidence interval 1.21-4.36, p = 0.001) for HR(0) ≥ 90 bpm relative to HR(0) < 90 bpm. No correlation was found between baseline heart rate and the secondary endpoint. From day 0 to day 4, heart rate remained elevated in all patients, as well as in survivors and non-survivors. CONCLUSIONS: A heart rate ≥90 bpm at the time of MODS diagnosis is an independent risk factor for increased 28-day mortality. As in patients with cardiovascular conditions such as coronary heart disease or chronic heart failure, heart rate might constitute a target for heart rate-lowering therapy in the narrow initial treatment window of MODS.
Authors: Finlay A McAlister; Natasha Wiebe; Justin A Ezekowitz; Alexander A Leung; Paul W Armstrong Journal: Ann Intern Med Date: 2009-06-02 Impact factor: 25.391
Authors: U Müller-Werdan; H Schumann; H Loppnow; R Fuchs; D Darmer; J Stadler; J Holtz; K Werdan Journal: J Mol Cell Cardiol Date: 1998-05 Impact factor: 5.000
Authors: Hendrik Schmidt; Ursula Müller-Werdan; Thomas Hoffmann; Darrel P Francis; Massimo F Piepoli; Mathias Rauchhaus; Roland Prondzinsky; Harald Loppnow; Michael Buerke; Dirk Hoyer; Karl Werdan Journal: Crit Care Med Date: 2005-09 Impact factor: 7.598
Authors: Ursula Muller-Werdan; Michael Buerke; Henning Ebelt; Konstantin M Heinroth; Anja Herklotz; Harald Loppnow; Martin Ruß; Frithjof Schlegel; Axel Schlitt; Hendrik B Schmidt; Gerold Söffker; Karl Werdan Journal: Exp Clin Cardiol Date: 2006
Authors: Wilhelm Grander; Kathrin Müllauer; Bernhard Koller; Herbert Tilg; Martin Dünser Journal: Clin Res Cardiol Date: 2013-04-27 Impact factor: 5.460
Authors: Lennaert Kleijn; B Daan Westenbrink; Vincent M van Deursen; Kevin Damman; Rudolf A de Boer; Hans L Hillege; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer Journal: Clin Res Cardiol Date: 2014-02-08 Impact factor: 5.460
Authors: Richard Steinacher; John T Parissis; Bernhard Strohmer; Jörg Eichinger; Dennis Rottlaender; Uta C Hoppe; Johann Altenberger Journal: Clin Res Cardiol Date: 2012-03-07 Impact factor: 5.460
Authors: Vincenzo De Santis; Domenico Vitale; Anna Santoro; Aurora Magliocca; Andrea Giuseppe Porto; Cecilia Nencini; Luigi Tritapepe Journal: Clin Res Cardiol Date: 2012-10-14 Impact factor: 5.460
Authors: Frank van Buuren; Klaus Peter Mellwig; Christian Prinz; Britta Körber; Andreas Fründ; Dirk Fritzsche; Lothar Faber; Tanja Kottmann; Nicola Bogunovic; Johannes Dahm; Dieter Horstkotte Journal: Clin Res Cardiol Date: 2013-04-12 Impact factor: 5.460
Authors: Peter Dolliner; Lindsay Brammen; Senta Graf; Martin Huelsmann; Leopold Stiebellehner; Andreas Gleiss; Philipp Ubl; Guenter Steurer Journal: Clin Res Cardiol Date: 2013-04-12 Impact factor: 5.460